Rapid molecular detection of tuberculosis and rifampin resistance

New England Journal of Medicine

Volumn 363, Issue 11, 2010, Pages 1005-1015

  Boehme, Catharina C ^a   Nabeta, Pamela ^a   Hillemann, Doris ^b   Nicol, Mark P ^c   Shenai, Shubhada ^e   Krapp, Fiorella ^f   Allen, Jenny ^d   Tahirli, Rasim ^g   Blakemore, Robert ^h   Rustomjee, Roxana ^d   Milovic, Ana ^c   Jones, Martin ⁱ   O'Brien, Sean M ^j   Persing, David H ⁱ   Ruesch Gerdes, Sabine ^b   Gotuzzo, Eduardo ^f   Rodrigues, Camilla ^e   Alland, David ^h   Perkins, Mark D ^a  

^a FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

^b RESEARCH CENTER BORSTEL   (Germany)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^e P D HINDUJA NATIONAL HOSPITAL   (India)

^f INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^g Special Treatment Institution   (Azerbaijan)

^h RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

ⁱ CEPHEID   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SPUTUM CULTURE; SPUTUM SMEAR; TUBERCULOSIS;

EID: 77956497725     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0907847     Document Type: Article

References (26)

1. Global tuberculosis control - epidemiology, strategy, financing: WHO report. Geneva: World Health Organization, 2009. (WHO/HTM/TB/2009.411.)
2. Perkins MD, Cunningham J. Facing the crisis: improving the diagnosis of tuberculosis in the HIV era. J Infect Dis 2007;196:Suppl 1:S15-S27. (Pubitemid 47206081)
3. Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 2007;369:2042-9.
4. Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 2008;300:423-30.
5. Uys PW, Warren RM, van Helden PD. A threshold value for the time delay to TB diagnosis. PLoS One 2007;2(1):e757.
6. Farmer P, Bayona J, Becerra M, et al. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis 1998;2:869-76.
7. Van Rie A, Enarson D. XDR tuberculosis: an indicator of public-health negligence. Lancet 2006;368:1554-6. (Pubitemid 44691898)
8. Palomino JC. Molecular detection, identification and drug resistance detection in Mycobacterium tuberculosis. FEMS Immunol Med Microbiol 2009;56:103-11.
9. Urdea M, Penny LA, Olmsted SS, et al. Requirements for high impact diagnostics in the developing world. Nature 2006;444:Suppl 1:73-9.
10. El-Hajj HH, Marras SA, Tyagi S, Kramer FR, Alland D. Detection of rifampin resistance in Mycobacterium tuberculosis in a single tube with molecular beacons. J Clin Microbiol 2001;39:4131-7.
11. Piatek AS, Tyagi S, Pol AC, et al. Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis. Nat Biotechnol 1998;16:359-63.
12. Raja S, Ching J, Xi L, et al. Technology for automated, rapid, and quantitative PCR or reverse transcription-PCR clinical testing. Clin Chem 2005;51:882-90.
13. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative: Standards for Reporting of Diagnostic Accuracy. Clin Chem 2003;49:1-6.
14. Kent PT, Kubica GP, eds. Public health mycobacteriology: a guide for the Level III laboratory. Atlanta: Centers for Disease Control, 1985.
15. Laboratory services in tuberculosis control. Geneva: World Health Organization, 1998. (WHO/TB/98.258.)
16. Cohn ML, Waggoner RF, McClatchy JK. The 7H11 medium for the cultivation of mycobacteria. Am Rev Respir Dis 1968;98:295-6.
17. Hillemann D, Rüsch-Gerdes S, Richter E. Application of the Capilia TB assay for culture confirmation of Mycobacterium tuberculosis complex isolates. Int J Tuberc Lung Dis 2005;9:1409-11. (Pubitemid 43265154)
18. Siddiqi SH, Ruesch-Gerdes S. MGIT procedure manual for BACTEC MGIT 960 TB System. Franklin Lakes, NJ: Beckton, Dickinson, July 2006.
19. Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010;48:229-37.
20. Blakemore R, Story E, Helb D, et al. Evaluation of the analytical performance of the Xpert MTB/RIF Assay. J Clin Microbiol 2010;48:2495-501.
21. Agresti A, Coull B. Approximate is better than "exact" for interval estimation of binomial proportions. Am Stat 1998;52:119-26.
22. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-30.
23. Stop TB Partnership: the global plan to stop TB 2006-2015. Geneva: World Health Organization, 2006.
24. Yagui M, Perales MT, Asencios L, et al. Timely diagnosis of MDR-TB under program conditions: is rapid drug susceptibility testing sufficient? Int J Tuberc Lung Dis 2006;10:838-43.
25. Urbanczik R, Rieder HL. Scaling up tuberculosis culture services: a precautionary note. Int J Tuberc Lung Dis 2009;13:799-800.
26. Banada PP, Sivasubramani SK, Blakemore R, et al. Containment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicability to point-ofcare settings. J Clin Microbiol 2010 August 18 (Epub ahead of print).